February 27, 2017 4:03 AM ET


Company Overview of OvaScience, Inc.

Company Overview

OvaScience, Inc., a fertility company, discovers, develops, and commercializes new fertility treatment options for women worldwide. The company’s patented technology is based on the discovery of egg precursor (EggPC) cells, which are immature egg cells found in the protective outer layer of a woman's own ovaries. It engages in developing and commercializing various fertility treatment options designed to enhance egg health and revolutionize in vitro fertilization (IVF) consisting of AUGMENT to enhance the energy and health of the woman’s eggs by using mitochondria from a woman's EggPC cells; OvaPrime treatment is used to replenish a woman's egg reserve by transferring the EggPCs from woman's...

9 Fourth Avenue

Suite 240

Waltham, MA 02451

United States

Founded in 2011

87 Employees



Key Executives for OvaScience, Inc.

Co-Founder and Executive Chairman
Age: 40
Compensation as of Fiscal Year 2015.

OvaScience, Inc. Key Developments

OvaScience, Inc. Presents at 35th Annual JP Morgan Healthcare Conference, Jan-12-2017 08:30 AM

OvaScience, Inc. Presents at 35th Annual JP Morgan Healthcare Conference, Jan-12-2017 08:30 AM. Venue: Westin St. Francis Hotel, 335 Powell Street, San Francisco, CA 94102, United States. Speakers: Michelle Dipp, Co-Founder and Executive Chairman.

Ovascience, Inc. Approves Amendments to Articles of Incorporation

On December 21, 2016, the Board of Directors of OvaScience approved an amendment to the company's Second Amended and Restated Bylaws. The purpose of the amendment is to allow the company to have a vacancy in the office of Chief Executive Officer.

OvaScience, Inc. Announces Executive Changes; to Reduce its Workforce by Approximately 30%

OvaScience, Inc. announced a business update. The company will continue to make AUGMENT available to patients at partner clinics in Canada and Japan and maintain its current commercial footprint. However, the company will slow its commercial expansion, reassess its ongoing and planned clinical studies of AUGMENT, and undertake a corporate restructuring. These changes will enable the company to extend its cash position into the first quarter of 2019 and increase its focus on the development of OvaPrime and OvaTure. In connection with this shift in strategy, President and Chief Executive Officer, Harald Stock, Ph.D. and Chief Operating Officer, Paul Chapman, who were brought on board have chosen to step down to seek new opportunities. Michelle Dipp, M.D., Ph.D., Executive Chair and co-founder of OvaScience, will oversee operations while the company conducts a comprehensive search for a new chief executive officer. The company will also reduce its workforce by approximately 30%.

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3Bar Biologics Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
The Advertising Council, Inc. United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact OvaScience, Inc., please visit www.ovascience.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.